This article summarized the latest R&D progress of carglumic acid, the Mechanism of Action for carglumic acid, and the drug target R&D trends for carglumic acid.
This article summarized the latest R&D progress of Regadenoson, the Mechanism of Action for Regadenoson, and the drug target R&D trends for Regadenoson.
This article summarized the latest R&D progress of Revefenacin, the Mechanism of Action for Revefenacin, and the drug target R&D trends for Revefenacin.
Structure Therapeutics has revealed encouraging results from its Phase 1b incremental dose study of its exclusive oral GLP-1 receptor agonist, GSBR-1290, in overweight or obese individuals.
This article summarized the latest R&D progress of Risedronate sodium, the Mechanism of Action for Risedronate sodium, and the drug target R&D trends for Risedronate sodium.
Amicus Therapeutics has confirmed that the U.S. FDA has given the green light to Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) 65mg capsules.